TCR-T Cell Recognition of an NY-ESO-1 Epitope Presented by HLA-A2 Supertype: Implications for Cancer Immunotherapy
Our study suggests that cancer patients expressing members of the HLA-A2 supertype may benefit from the TCR-T cell product, and other TCR-T cell products could similarly expand their population coverage even within the non-Chinese population through an analogous approach.
Authors
- Tong Lin (ORCID: https://orcid.org/0009-0002-9822-1700)
- Xiaojun Xia (ORCID: https://orcid.org/0000-0003-4444-7472)
- Yipeng Ma
- Qingqing Lin (ORCID: https://orcid.org/0009-0002-6741-0875)
- Fenglan Liu (ORCID: https://orcid.org/0000-0002-0973-775X)
- Jinling Zhang (ORCID: https://orcid.org/0000-0003-3419-6542)
- Zhi Wang (ORCID: https://orcid.org/0000-0002-5276-1413)
- Xiaochun Chen (ORCID: https://orcid.org/0000-0002-2665-4155)
- Yanwei Li (ORCID: https://orcid.org/0000-0002-7381-4158)
- Mingjun Wang (ORCID: https://orcid.org/0000-0002-1020-3915)
- Heng Sun (ORCID: https://orcid.org/0000-0001-9091-4591)
- Jin Shi (ORCID: https://orcid.org/0000-0002-5148-9075)
- Geng Tian (ORCID: https://orcid.org/0000-0001-7267-3771)
Institutions
- Sun Yat-sen University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Shenzhen Institute of Innovation Design (China) (CN)
- Lifetech Scientific (China) (CN)
- University of Hong Kong - Shenzhen Hospital (CN)
- Sun Yat-sen University Cancer Center (CN)
- Shenzhen Second People's Hospital (CN)
- Hainan Medical University (CN)
Publication Details
- Journal
- Vaccines
- Published
- 2025-08-25
- DOI
- https://doi.org/10.3390/vaccines13090898
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Chinese Academy of Medical Sciences
- Shenzhen Peacock Plan
- Basic and Applied Basic Research Foundation of Guangdong Province